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Scope: This study examines the long-term functional effects of D-fagomine on sucrose- 3 
induced factors of metabolic dysfunctions and explores possible molecular mechanisms 4 
behind its action. 5 
Methods & results: Wistar Kyoto (WKY) rats were fed a 35% sucrose solution with D-6 
fagomine (or not, for comparison) or mineral water (controls) for 24 weeks. We 7 
recorded: body weight; energy intake; glucose tolerance; plasma leptin concentration 8 
and lipid profile; populations of Bacteroidetes, Firmicutes, bacteroidales, clostridiales, 9 
enterobacteriales, and Escherichia coli in feces; blood pressure; urine uric acid and F2t10 
isoprostanes (F2-IsoPs); perigonadal fat deposition; and hepatic histology and 11 
diacylglycerols (DAGs) in liver and adipose tissue. 12 
D-Fagomine reduced sucrose-induced hypertension, urine uric acid and F2-IsoPs 13 
(markers of oxidative stress; OS), steatosis and liver DAGs, without significantly 14 
affecting perigonadal fat deposition and impaired glucose tolerance. It also promoted 15 
excretion of enterobacteriales generated by the dietary intervention. 16 
Conclusion: D-fagomine counteracts sucrose-induced steatosis and hypertension, 17 
presumably by reducing the postprandial levels of fructose in the liver. 18 
19 
4 
1. Introduction 20 
s[1]Central fat accumulation and hypertension are risk factors for cardiovascular disease 21 
(CVD). Together with insulin resistance (IR), they are part of the cluster of factors 22 
known as metabolic syndrome (MetS)  [1]. 23 
Dietary-fat-induced central adiposity results in ectopic fat deposition when 24 
subcutaneous adipocytes become insulin resistant and lose their capacity to store 25 
triacylglycerols, which are then deposited at undesirable sites such as the liver, the 26 
heart, the skeletal muscle or visceral adipose tissue (VAT) [2]. Then visceral adipocytes 27 
become resistant to the antilipolytic effect of insulin and free fatty acids  drain directly 28 
into the liver through the portal vein, leading to impaired liver metabolism [3]. In 29 
contrast, sucrose (glucose/fructose)-induced adiposity develops through other pathways 30 
linked primarily to the excess of fructose. Unlike glucose, fructose is almost entirely 31 
catabolized, mainly in the liver, and escapes metabolic control by insulin [4]. Apart 32 
from contributing substrates for de novo liposynthesis (DNL), fructose may increase 33 
hepatic lipid levels by activating modulators of liposynthesis such as sterol receptor 34 
element binding protein–1c (SREBP-1c) [5]. Fructose-driven DNL also contributes to 35 
liver fat accumulation by inhibiting the hepatic oxidation of endogenous and exogenous 36 
fatty acids via increased levels of malonyl-coA [6]. Hepatic DNL triggers postprandial 37 
hypertriglyceridemia, which may promote lipid deposition as VAT rather than as 38 
subcutaneous adipose tissue [7]. 39 
As adipose tissue (AT) is a source of angiotensinogen, adiposity may lead to 40 
hypertension via activation of the renin-angiotensin-aldosterone system (RAAS) [8]. 41 
Free fatty acids from VAT may stimulate the RAAS via aldosterone production 42 
independently of renin [8], and they may also trigger hypertension via activation of the 43 
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sympathetic nervous system [9]. Increased levels of uric acid may contribute to 44 
hypertension through systemic and renal vasoconstriction by increasing intracellular 45 
oxidative stress (OS), activating the RAAS, and inhibiting the production of endothelial 46 
nitric oxide (NO) [10]. 47 
D-Fagomine (1,2-dideoxynojirimycin) is a polyhydroxylated nitrogen-containing ring 48 
structurally related to glucose and mannose. It is a minor component of buckwheat 49 
(Fagopyrum esculentum Moench, Polygonaceae) and traditional buckwheat-based 50 
foodstuffs such as noodles, pancakes, fried dough, beer, cookies and bread [11]. In rats, 51 
D-fagomine reduces elevated plasma insulin concentrations induced by a high-fat (HF) 52 
diet (Sprague-Dawley rats, 9 weeks) [12] and it counteracts fat-induced low-grade 53 
inflammation and impaired glucose tolerance (IGT) (Wistar Kyoto (WKY) rats, 13-21 54 
weeks) via a mechanism that may involve modifications of gut microbiota [13]. As D-55 
fagomine is poorly absorbed [14], it is likely to be largely in contact with the intestinal 56 
wall. There, D-fagomine also delays starch and sucrose digestion by inhibiting brush 57 
border glycosidases [15]. In previous work we have shown that an excess of fat or 58 
sucrose (glucose/fructose) triggers different risk factors of MetS at different times in 59 
WKY rats: an HF diet induced obesity and fast onset IR and IGT via low-grade 60 
inflammation; while a high-sucrose (HS) diet induced IGT later than the HF diet, 61 
through liver DNL from fructose. Meanwhile, only the HS diet triggered elevated blood 62 
pressure [16]. After reporting the long-term functional effect of D-fagomine on fat-63 
induced MetS factors [13], we here examine its effects on sucrose-induced factors, 64 
namely VAT, fatty liver, IGT and hypertension.65 
2. Materials and Methods 66 
2.1 Animals 67 
6 
A total of twenty-seven male WKY rats from Envigo (Indianapolis, IN, USA), aged 8-9 68 
weeks were used. All animal manipulation was carried out in the morning to minimize 69 
the effects of circadian rhythms. All the procedures strictly adhered to the European 70 
Union guidelines for the care and management of laboratory animals and were licensed 71 
by the Catalan authorities (reference no. DAAM7921), as approved by the Spanish 72 
CSIC Subcommittee of Bioethical Issues. 73 
74 
2.2 Experimental Design and Sample Collection 75 
The rats were kept under controlled conditions of humidity (60%), and temperature (22 76 
± 2 ºC) with a 12 h light-12 h dark cycle. They were randomly divided into 3 dietary 77 
groups (n = 9 per group), all fed a standard feed (2014 Teklad Global 14% Protein) 78 
from Envigo ad libitum with free access to water or sucrose solutions as follows: the 79 
standard (STD) group was given mineral water (Ribes, Girona, Spain); the HS group 80 
was given a 35% sucrose solution in mineral water as the only source of liquid intake; 81 
and the HS with D-fagomine (HS+FG) group was given a 35% sucrose solution in 82 
mineral water supplemented with D-fagomine (> 98% from Bioglane SLNE; Barcelona, 83 
Spain). The dosage of D-fagomine was the same used in the previous HF study (2 mg 84 
per g carbohydrate) [13]. 85 
Feed and drink consumptions were monitored daily and body weight was measured 86 
weekly throughout the experiment. Energy intake was estimated as metabolizable 87 
energy based on the Atwater factors:4 kcal per g protein, 9 kcal per g fat, and 4 kcal per 88 
g available carbohydrate. Fecal samples were collected by abdominal massage after 89 
week 20. The energy content of the feces was determined by differential scanning 90 
calorimetry (25-600 ºC in an O2 atmosphere, 10 ºC min‒1) by means of a 91 
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thermogravimetric analyzer TGA/SDTA 851e (Mettler Toledo; Columbus, OH, USA) 92 
with an integrated SDTA signal. 93 
After week 23, the rats were placed in metabolic cages overnight for urine collection. At 94 
the end of the experiment (week 24), the rats were anaesthetized intraperitoneally with 95 
ketamine and xylazine (80 and 10 mg per kg body weight, respectively) after overnight 96 
fasting. Blood was collected by cardiac puncture then plasma was immediately obtained 97 
by centrifugation and stored at −80 ºC until analysis. Perigonadal AT, a type of VAT in 98 
rats [17], and liver were removed, weighed and cut into small pieces. One part of the 99 
liver was fixed in 10% formalin for histological analysis. The rest of the liver and 100 
adipose tissue were washed with 0.9% NaCl solution and stored at −80 ºC for DAG 101 
analysis. 102 
103 
2.3 Oral Glucose Tolerance Test, Fasting Glucose and Plasma Insulin 104 
After weeks 13 and 21, an oral glucose tolerance test (OGTT) was performed on 105 
overnight fasted animals. A solution of glucose (1 g per kg body weight) was 106 
administered to the rats by oral gavage. Blood glucose concentration was measured by 107 
the enzyme electrode method using an Ascensia ELITE XL blood glucose meter (Bayer 108 
Consumer Care AG; Basel, Switzerland) before the experiment and 15, 30, 45, 60, 90 109 
and 120 min after glucose intake. Fasting blood glucose was measured by the same 110 
method after week 24 on animals fasted overnight. Plasma insulin was determined on 111 
these samples using Milliplex xMAP multiplex technology on a Luminex xMAP 112 
instrument (Millipore, Austin, TX). Milliplex Analyst 5.1 (Vigenetech, Carlisle, PA, 113 
USA) software was used for data analysis. The standard curve was generated for the 114 




2.4 Plasma Lipid Profile and Leptin Concentration 118 
Total plasma cholesterol, HDL and LDL cholesterol, and triglycerides were all 119 
measured by spectrophotometric methods using the corresponding kits from Spinreact 120 
(Girona, Spain) as described elsewhere [18]. Leptin levels were measured together with 121 
insulin using the Milliplex xMAP multiplex technology (Millipore).  122 
123 
2.5 Fecal Microbiota 124 
The levels of total bacteria and Bacteroidetes, Firmicutes, Enterobacteriales, and 125 
Escherichia coli were estimated from fecal DNA by quantitative real-time PCR (qRT-126 
PCR). DNA was extracted from the feces using the QIAamp DNA StoolMini Kit from 127 
Qiagen (Hilden, Germany) and  quantified using a Nanodrop 8000 Spectrophotometer 128 
(Thermo Scientific; Waltham, MA, USA).  were  qRT-PCR was carried out in triplicate 129 
on diluted DNA samples (20 ng µL−1), using a LightCycler 480 II (Roche; Basel, 130 
Switzerland). Eachreaction mixture contained DNA solution (2 µL) and a master mix 131 
(18 µL) made of 2XSYBR (10 µL), the corresponding forward and reverse primer (1 µL 132 
each), and water (6 µL).  Both Nontemplate controls (water) and  positive controls were 133 
included. The primers and annealing temperatures are detailed in Table S1, Supporting 134 
Information. The PCR cycling conditions were: 10 s at 95 °C, then 45 cycles of 5 s at 95 135 
°C, 30 s at the primer-specific annealing temperature (Table S1, Supporting 136 
Information), and 30 s at 72 °C (extension). To determine the specificity of the qRT-137 
PCR after amplification, melting curve analysis was carried out: 2 s at 95 °C, 15 s at 65 138 
°C, followed by atemperature gradient up to 95 °C at a rate of 0.11 °C s−1, with five 139 
fluorescence readings per °C. The relative DNA abundances for the different genes 140 
were calculated from the second derivative maximum of their respective amplification 141 
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curves (Cp, calculated in triplicate) by considering Cp values to be proportional to the 142 
dual logarithm of the inverse of the specific DNA concentration, according to the 143 
equation: [DNAa]/[DNAb] = 2Cpb-Cpa [19]. Total bacteria was normalized as 16S 144 
rRNA gene copies per mg of wet feces (copies per mg). 145 
146 
2.6 Blood Pressure, and Urine and Plasma Uric Acid 147 
Systolic and diastolic blood pressure was measured at time 0 and after weeks 4, 9, 15 148 
and 22 by the tail-cuff method, using a non-invasive automatic blood pressure analyzer 149 
(Harvard Apparatus, Holliston, MA, USA). 150 
Total urine and plasma uric acid were determined by a spectrophotometric method using 151 
a uricase/peroxidase kit from BioSystems (Barcelona, Spain) via measuring the 152 
absorbance at 520 nm on a SpectraMax M5 spectrophotometer (Molecular Devices, 153 
Sunnyvale, CA, USA). Creatinine levels in urine were determined by a colorimetric 154 
method using a commercial kit (C-cromatest Linear Chemicals, Montgat, Spain) via 155 
measuring absorbance at 510 nm. 156 
157 
2.7 Measurement of Isoprostanes158 
F2-isoprostanes (F2-IsoPs) were determined in urine samples by LC/ESI–MS/MS 159 
following a previously reported procedure [12] with some modifications. Samples (500 160 
µL) were acidified and the mixtures were incubated for 2 h at 37 ºC in the presence of 161 
β-glucuronidase (90 U mL‒1) (Sigma, Saint Louis, MI, USA). , F2-IsoPs were purified 162 
by SPE after adding [2H4]15-F2t-IsoP (Cayman, Ann Arbor, MI, USA) (internal 163 
standard 100 µL, 10 µg L‒1) and analyzed using an Agilent 1260 chromatograph 164 
coupled to a 4000 QTRAP mass spectrometer (Applied Biosystems, Foster City, CA, 165 
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USA) fitted with a Mediterranea Sea 18 column (10 cm x 2.1 mm i.d., 2.2 µm particle 166 
size) (Teknokroma, Barcelona, Spain). The instrument was operated in the negative-ion 167 
mode with a Turbo V source to obtain MS/MS data. The chromatography solvents used 168 
were  [A] 0.1% aqueous formic acid and [B] 0.1% formic acid in acetonitrile, and the 169 
solutes were separated with an increasing linear gradient (v/v) of [B]: time 0, 10% B; 7 170 
min, 50% B; 7.1 min, 100% B; 8 min, 100% B; 8.1 min, 10% B; and 10 min, 10% B, at 171 
a flow rate of 700 µL min‒1 at 40 ºC. F2-IsoPs were detected by  multiple reaction 172 
monitoring (MRM). Calibration curves were prepared using seven matrix-matched 173 
standards covering the working concentration range. The LOQ was 0.4 µg L‒1 for 15-174 
F2t-IsoP and 2 µg L‒1 for 5-F2t-IsoP. The results were expressed as ng per mg creatinine, 175 
to correct for urine dilution. 176 
177 
2.8 Histology of the Liver 178 
Formalin fixed livers were dehydrated in alcohol and embedded in paraffin (Panreac 179 
Quimica SLU; Barcelona, Spain), and then cut into 3 µm thick slices, using a steel knife 180 
mounted in a microtome (HM 355S Rotary Microtome; Thermo Fisher Scientific, 181 
Waltham, MA, USA). Sections were stained with hematoxylin (Hematoxylin solution 182 
modified according to Gill III for microscopy; Merck KGaA, Darmstadt, 183 
Germany)/eosin (Pharmacy Service of Puerta del Mar Hospital, Cádiz, Spain) then 184 
viewed under a light microscope (NIKON Eclipse 80i; NIKON Corporation, Minato, 185 
Japan). Three parameters were graded following the method described by Taltavull et al 186 
[20]: steatosis, 0 (<5%), 1 (5%–33%), 2 (33%–66%), or 3 (>66%); steatosis 187 
localization, 0 (absence), 1 (periportal), or 2 (non-zonal); and the presence of 188 
lipogranuloma, 0 (absence) or 1 (presence).  189 
190 
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2.9 Diacylglycerols in Liver and Adipose Tissue 191 
Frozen samples were thawed and homogenized by sonication on a  SFX150 Sonifier 192 
(Emerson Industrial Automation, St. Louis, MO, USA). DAGs  were  analyzed using 193 
the method described by Simbari et al [21] with some modifications. The  internal 194 
standard was  1,3-17:0 D5 DG (Avanti Polar Lipids Inc., Alabaster, AL, USA; 200 195 
pmol) and the incubation conditions were  12 h  at 48 ºC. Then the  samples were dried 196 
and suspended in methanol, centrifuged (9390 g, 3 min) and the supernatants (8 µL) 197 
loaded into an Acquity UPLC separation system connected to an LCT Premier 198 
orthogonal accelerated time-of-flight mass spectrometer (Waters; Milford, MA, USA), 199 
operated in positive ESI mode (LC-TOF-MS). DAG resolution was achieved using a C8 200 
Acquity UPLC-bridged ethylene hybrid 100 x 2.1 mm i.d., 1.7 m column (Waters) and 201 
a binary elution system consisting of [A] 0.2% (v/v) formic acid, 2 mM ammonium 202 
formate in water and [B] the same buffer in methanol, under linear gradient conditions: 203 
0.0 min, 80% B; 3 min, 90% B; 6 min, 90% B; 15 min, 99% B; 18 min, 99% B; 20 min, 204 
80% B; and 22 min, 80% B, at 30 ºC. The flow rate was 0.3 mL min‒1. Full-scan spectra 205 
from 50 to 1,500 Da were acquired, and individual spectra were summed to produce 206 
data points of 0.2 s each. To maintain mass accuracy and precision  leucine enkephalin 207 
was used as an independent reference spray () via the LockSpray interface.. 208 
Quantification was carried out using the extracted ion chromatogram of each compound, 209 
with 50 mDa windows. The linear range was determined by injecting mixtures of 210 
internal standards. DAG content was calculated as DAG 16:0, 16:0 equivalents. 211 
212 
2.10 Statistical Analysis 213 
Statistical analysis  was performed using Graph Pad Prism 5 (Graph Pad Software, Inc., 214 
San Diego, CA, USA). Quantitative data are expressed as mean values with their 215 
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standard errors (SEM). Normal distributions and heterogeneity of the data were 216 
evaluated and statistical significance was determined by two-way ANOVA for repeated 217 
measures (OGTT). One-way ANOVA, and Tukey’s multiple-comparison test were used 218 
for mean comparison. Differences were considered significant when P < 0.05. The 219 
results from qualitative measurements of histological sections are expressed in 220 
frequencies (percentage of animals that present the value, or do not) and their statistical 221 
significance was determined using contingency tables and χ2 statistics.  222 
223 
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3. Results 224 
3.1. Feed and Drink Intakes, Energy Balance, and Body and Perigonadal Adipose 225 
Tissue Weights 226 
Feed intake was lower and drink intake was higher in both HS (HS and HS+FG) groups 227 
than in the STD group (Table 1). The glucose/fructose intake was similar in the HS and 228 
HS+FG groups. Energy intake was higher in both HS groups than in the STD group; 229 
while energy in feces was similar in all three groups studied (Table 1).  230 
Body weight was similar in all of the groups at the beginning (234.8 g, SEM 3.2), and 231 
no differences were observed between the STD and either HS group throughout the 232 
experiment (Table 1). Perigonadal AT weight was significantly higher in the HS and 233 
HS+FG groups (P <0.001) and (P <0.01, respectively) (Table 1). 234 
235 
3.2 Glycemic Status.  236 
The OGTT test was run after weeks 13 and 21. There were no significant differences 237 
between groups after week 13 (Figure 1A). After week 21, the levels of  postprandial 238 
glucose in animals that consumed an excess of sucrose (HS and HS+FG groups) were 239 
higher (P < 0.01) than those in the STD group, 30 and 45 min after glucose 240 
administration (Figure 1B). At 60 and 90 min after administration, the levels of plasma 241 
glucose were higher (P < 0.01) in the HS than the STD group; while there was no 242 
difference between the STD and HS+FG groups.  243 
Fasting blood glucose was below 70 mg dL‒1 in all three groups after week 21 and at the 244 
end of the study (week 24) (Figure 1, Table 2). Fasting plasma insulin was significantly 245 
higher in animals given either HS diet (HS and HS+FG groups) (Table 2). 246 
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247 
3.3 Plasma Leptin and Lipid Profile  248 
Plasma leptin was higher (P < 0.001) in the HS group than in the STD group (Table 2). 249 
Total and LDL cholesterol in plasma were similar in all the groups (Table 2). HDL 250 
cholesterol levels were higher (P<0.05) in the HS and HS+FG groups than in the STD 251 
group. Plasma triglyceride levels were higher in both HS groups than in the STD group, 252 
but this difference was only significant (P<0.05) between the HS+FG group and the 253 
STD group. 254 
255 
3.4 Fecal Microbiota 256 
The proportions of bacterial phyla, orders and E. coli in the gut microbiota were 257 
evaluated after week 24 (Table 3). The Bacteroidetes, bacteroidales, enterobacteriales 258 
and E. coli populations in feces were significantly higher (P < 0.05) in both HS groups. 259 
The highest populations were recorded in the D-fagomine supplemented group. 260 
261 
3.5 Blood Pressure and Uric Acid in Urine and Plasma 262 
After 23 weeks of sucrose intake, systolic (Figure 2A) and diastolic (Figure 2B) blood 263 
pressures were significantly higher (P < 0.05) in animals fed the HS diet than in those 264 
fed the STD or HS+FG diets. Animals in the two groups that consumed an excess of 265 
sucrose (HS and HS+FG) presented a significantly (P < 0.001) higher concentration of 266 
urine uric acid than those of the STD group after week 23 (Figure 2C). The group 267 
supplemented with D-fagomine (HS+FG) presented significantly (P < 0.05) lower 268 
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concentration of urine uric acid than the HS group and the lowest concentration among 269 
groups in plasma (Figure 2C, D). 270 
271 
3.6 Urine Isoprostanes 272 
The animals fed the HS diet presented increased concentrations of 5-F2t-IsoP and 15-273 
F2t- IsoP (P < 0.05) compared with the STD group after 23 weeks of intervention 274 
(Figure 3A, B); while the animals supplemented with D-fagomine (HS+FG group) 275 
presented concentrations of IsoPs similar to those in the STD group (Figure 3A, B). 276 
277 
3.7 Liver Histology  278 
An excess of sucrose induced significant (P < 0.001) and highly localized steatosis 279 
(Figure 4B, C, D) and lipogranuloma (P < 0.001; Figure 4E). D-Fagomine 280 
supplementation (HS+FG group) significantly (P < 0.001) reduced the grade of 281 
steatosis, from 2 (33%-66% steatosis) in the HS group to 1 (5%-33% steatosis), with no 282 
influence on its localization. Lipogranuloma was less (P < 0.001) present in animals in 283 
the HS+FG group than in those in the HS group (Figure 4E).  284 
285 
3.8 Liver and Adipose Tissue Diacylglycerols 286 
The levels of DAGs 32:1, 32:2, 34:1 and 36:2 were higher in livers from rats in the HS 287 
group than from those in the STD and HS+FG groups (Figure 5 and Table S2, 288 
Supporting Information). There were no significant differences in any DAG content 289 
between the HS and HS+FG groups in AT (Table S3, Supporting Information).290 
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4. Discussion 291 
The present study explores the effects of D-fagomine on a rat model of sugar-induced 292 
metabolic alterations. From previous work we knew that WKY rats given a 35% 293 
sucrose (glucose/fructose) solution as the only source of liquid intake present moderate 294 
IGT, steatosis, deposition of perigonadal AT and raised blood pressure after 21-24 295 
weeks of intervention, while remaining normoweight [16]. Here, we show that D-296 
fagomine can counteract this induced steatosis and the elevation in blood pressure, 297 
while it had little effect on perigonadal fat (Table 1) and IGT (Figure 1). Gonadal AT is 298 
a type of VAT in rats [17] that has been associated with low-grade inflammation and 299 
metabolic complications, mainly owing to the production of free fatty acids and 300 
proinflammatory adipokines by adipocytes [2, 22]. Therefore, the increase in VAT may 301 
account, at least in part, for the IGT observed in the groups fed HS diets. Direct 302 
disruption of insulin signaling by lipid metabolites such as DAGs may also contribute to 303 
the sucrose-induced IGT [7, 16]. Fat accumulation and generation of DAGs in the liver 304 
would result from fructose-induced DNL [4]. Fructose-induced DNL is believed to 305 
trigger fat deposition in VAT by supplying triglycerides from the liver via upregulation 306 
of very-low-density lipoprotein (VLDL) production and secretion [7]. In 307 
contradistinction to this view, our observation that D-fagomine reduced steatosis (Figure 308 
4) and not perigonadal fat deposition (Table 1) suggests that fructose-induced visceral 309 
fat accumulation may proceed independently of liver DNL. This hypothesis is supported 310 
by previous evidence that overconsumption of fructose may lead to rapid inflammation 311 
in subcutaneous adipocytes and an increase in intracellular cortisol that stimulates the 312 
flux of fatty acids into VAT [23] independently of any effect in the liver. The fact that 313 
D-fagomine only reduced fat deposition in the liver might be connected to its inhibitory 314 
activity on intestinal sucrase [15]. As fructose is mainly accumulated in the liver [4], 315 
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this organ may be more sensitive than AT to variations in fructose concentration. 316 
Therefore, as D-fagomine consistently reduces postprandial blood glucose/fructose 317 
levels by 25% at the dose supplied via the drink (2 mg per g sucrose) [15], it may be 318 
reducing liver DNL through lowered activation of regulatory factors such as SREBP-1c 319 
[5]. This reduction in liver DNL is consistent with the observation that D-fagomine 320 
maintains the levels of liver DAGs similar to those in the STD group, while they are 321 
significantly elevated (P < 0.05) in the HS group (Figure 5). In contrast, D-fagomine did 322 
not modify DAG levels in perigonadal AT with respect to the HS group (Table S3, 323 
Supporting Information), which confirms that a reduction in postprandial fructose 324 
concentration would not significantly affect DNL in AT. The reduction of liver DAGs 325 
may account, at least in part, for the slight effect of D-fagomine on sucrose-induced IGT 326 
recorded at the end of the study (Figure 1, time 90).  327 
D-Fagomine also affected the levels of fasting leptin: an anorectic hormone that helps to 328 
regulate energy expenditure [24], produced by white AT and other organs [25]. In 329 
agreement with studies on both rodents and humans [26, 27], fasting plasma leptin 330 
levels where significantly higher (P < 0.001) in animals given an excess of sucrose than 331 
in those given the STD diet (Tables 1 and 2). WKY rats supplement with D-fagomine 332 
presented levels of fasting leptin similar to those in the STD group (Table 2). In a 333 
similar experiment, Sprague-Dawley rats given free access to a 30% sucrose solution 334 
developed insulin sensitivity-independent leptin resistance that was rapidly reverted 335 
(days) after the excess of sucrose was eliminated from the diet [28]. This suggests that 336 
adiposity as such may not be a major contributor to leptin resistance in that model. The 337 
reduction of postprandial glucose/fructose concentration might be responsible for the 338 
effect of D-fagomine on circulating leptin. 339 
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The animals consuming an excess of sucrose without D-fagomine supplementation (HS 340 
group) showed elevated blood pressure (Figure 2) without increased body weight (Table 341 
1) in agreement with other studies [16, 29-31]. The reduction of circulating fructose 342 
levels may also explain the D-fagomine-mediated reduction in blood pressure (Figure 343 
2). High levels of liver fructose triggers elevated blood pressure by generating an excess 344 
of uric acid via overexpression of fructokinase C, increased ATP consumption and 345 
nucleotide turnover [10, 16, 32]. Lower levels of postprandial fructose in the 346 
supplemented group would be consistent with the reduction in the levels of urine and 347 
plasma uric acid (Figure 2), which may explain, at least in part, the effect of D-fagomine 348 
on lowering blood pressure. The levels of uric acid did not increase in plasma (Figure 349 
2). This may be because urine concentration was measured in fasted animals while the 350 
physiologically relevant high levels of plasma uric acid are likely to occur in the 351 
postprandial period. In fasted animals, the levels of uric acid in urine are more likely to 352 
reflect chronic effects of fructose consumption. Additionally to affecting uric acid, D-353 
fagomine may counteract the possible hypervolemic effect induced by a chronic high 354 
intake of sucrose [29], also by lowering the circulating levels of glucose/fructose. D-355 
Fagomine also prevented the sucrose-induced systemic OS, which was monitored by 356 
measuring urine F2-IsoPs (Figure 3). This late (week 24) OS does not seem to be a 357 
direct consequence of IR or IGT [16], while it may be related to elevated blood pressure 358 
via generation of uric acid [33].  359 
The role of intestinal microbiota in host homeostasis is increasingly being revealed [34]. 360 
At the phylum level, a reduced Bacteroidetes/Firmicutes ratio compared to the lean 361 
phenotype has been associated with the obese phenotype in both humans and mice [35, 362 
36]. In our experiment, the HS diet (HS and HS+FG groups) did not affect the 363 
populations of the phylum Firmicutes in the gut microbiota of WKY rats while it 364 
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triggered a slight increase in Bacteroidetes that was more evident in the supplemented 365 
group (Table 3). This is consistent with the absence of weight gain differences between 366 
the STD, HS and HS+FG groups (Table 1). The populations of Enterobacteriales, and 367 
particularly E. coli, were higher (P < 0.05) in the HS group than the STD group (Table 368 
3). Previously, we have suggested elsewhere that this may be connected to an increase 369 
in uric acid excreted via feces, which would foster the proliferation of Enterobacteriales 370 
[16]. The inhibitory activity of D-fagomine on epithelial adhesion of E. coli [15] would 371 
therefore explain the increase in excreted Enterobacteriales in the supplemented group 372 
(Table 3). 373 
In conclusion, D-fagomine counteracted sucrose-induced  fatty liver and elevated blood 374 
pressure in rats. The maintenance  of DAG levels in the liver, though not in VAT, 375 
together with the effect of lowering uric acid concentrations suggest that D-fagomine 376 
selectively influences liver function, probably by reducing the levels of postprandial 377 
fructose as a result of its inhibitory activity on intestinal sucrase. The selective action of 378 
D-fagomine also suggests that fat deposition in VAT is not a direct consequence of liver 379 
DNL in rats fed an excess of sucrose. As D-fagomine has been proven to lower 380 
postprandial blood glucose/fructose levels in healthy volunteers (sucrose loading test, 381 
clinical trial accessible at https://clinicaltrials.gov/ct2/show/NCT01811303), it is 382 
reasonable to expect a protective action against in humans consuming an excess of 383 
sucrose.  The amount of D-fagomine consumed daily by the rats in this study (ca. 98 mg 384 
kg-1 body weight) would translate to 15.5 mg kg-1 in humans by following the 385 
conversion proposed by Reagan-Shaw et al. [37]. This dose is higher than the amount 386 
provided by a diet rich in buckwheat-based foodstuffs [14] therefore, it should be 387 
reached by dietary supplementation. The present results, together with the previous 388 
report of the action on fat-induced low-grade inflammation, IR and IGT, are suggesting 389 
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that D-fagomine may be effective at preventing MetS by acting on different risk factors 390 
triggered by different components of unhealthy Westernized diets, such as excessive 391 
intake of saturated fat and refined sugar. 392 
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Tables 
Table 1.- Feed, drink, and energy intake; and body and perigonadal AT weights of 
WKY rats fed the different diets for 24 weeks. Also, residual excreted energy in feces 
after 20 weeks of intervention. 
STD HS HS+FG
Mean SEM Mean SEM Mean SEM
Feed intake (g per 
day per 100 g body 
weight) 
5.4 0.2 2.8* 0.1 2.8* 0.1 
Drink intake (mL
per day per 100 g 
body weight) 
7.4 0.2 10.5* 0.2 9.5* 0.2 
Fructose intake (g
per day per 100 g 
body weight) 
‒a  1.4 0.0 1.4 0.2 
Total energy intake 
(kcal per day per 
100 g body weight)
15.6 0.4 22.6* 0.5 21.5* 0.5 
Energy in feces 
kcal °C g‒1b
310 20 290 20 260 20 




8 0 13*** 1 12** 1 
Data are presented as means with their standard errors of the mean; n = 9 per group. 
Comparisons were performed using one-way ANOVA and Tukey’s multiple-
comparison test. * P < 0.05, ** P < 0.01, *** P < 0.001 vs STD group 
a Fructose intake as part of the 2014 Teklad Global feed is negligible compared to that in 
the HS diets. 
b Integrated STDA signal ( proportional to energy. 
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Table 2.- Fasting glucose and insulin, lipid profile and leptin in plasma of WKY rats 
fed different diets for 24 weeks. 
STD HS HS+FG
Mean SEM Mean SEM Mean SEM
Fasting glucose 
(mg dL‒1) 69 2 65 3 62* 1 
Fasting insulin (ng 
mL‒1) 0.4 0.1 0.8* 0.2 1.3* 0.5 
Leptin (ng mL‒1) 2.5 0.3 5.4*** 0.6 3.9 0.4 
Total cholesterol 
(mg dL‒1) 135 4 132 3 132 2 
HDL cholesterol 
(mg dL‒1) 49 1 54* 2 53* 1 
LDL cholesterol 
(mg dL‒1) 23 2 21 1 22 1 
Triglycerides (mg
dL‒1) 60 6 90 10 110* 10 
Data are presented as means with their standard errors of the mean; n = 9 per group. 
Comparisons were performed using one-way ANOVA and Tukey’s multiple-
comparison test. * P < 0.05, and *** P < 0.001 vs STD group 
25 
Table 3.- Excreted intestinal bacteria (% copies per total bacteria) from rats fed 
different diets for 24 weeks. 
STD HS HS+FG
Mean SEM Mean SEM Mean SEM
Bacteroidetes 30 3 80** 10 110*** 10 
Firmicutes 37 4 57 10 38 2 
Bacteroidales 40 4 60* 6 73*** 5 
Clostridiales 12 2 15 2 14 2 
Enterobacteriales 0.01 0.00 0.07* 0.03 0.14***δ 0.02 
E. coli 0.004 0.003 0.040* 0.012 0.135*** δ 0.032
Data are presented as means with their standard errors of the mean; n = 9 per group. 
Comparisons were performed using one-way ANOVA and Tukey’s multiple-
comparison test. * P < 0.05, and *** P < 0.001 vs STD group; δ P < 0.05 vs HS group 
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Figure 1. Time course of plasma glucose concentration after administration of a single 
dose of glucose (1 g per kg body weight) to WKY rats fed a standard (STD), high-
sucrose (HS), or high-sucrose supplemented with D-fagomine (HS+FG) diet for 13 (A) 
and 21 (B) weeks.  
Values are means with their standard errors. Comparisons were performed using one-
way ANOVA and Tukey’s tests or two-way ANOVA. ** P < 0.01 and *** P < 0.001 vs
STD group. 
Figure 2. Systolic (A) and diastolic (B) blood pressure, and uric acid in urine (C) and 
plasma (D) in rats fed a standard (STD, ○), high-sucrose (HS, □), or high-sucrose with 
D-fagomine (HS+FG, ■) diet for 24 weeks. Results are represented as means with their 
standard errors.  
Comparisons were conducted using one-way ANOVA and Tukey’s multiple-
comparison test. * P < 0.05, ** P < 0.01 and *** P < 0.001 vs STD group; δ P < 0.05, 
δδ P < 0.01 vs HS group.
Figure 3. 5-F2t isoprostane (A) and 15-F2t  isoprostane (B) in urine from WKY rats fed 
a standard (STD), high-sucrose (HS), or high-sucrose with D-fagomine (HS+FG) diet 
for 24 weeks of nutritional intervention.  
Results are represented as means with their standard errors. Comparisons were 
conducted using one-way ANOVA and Tukey’s multiple-comparison test. * P < 0.05 vs
STD group 
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Figure 4. Histological sections (hematoxylin/eosin stained) from the livers of WKY rats 
fed a standard (STD) (A, 10x), high-sucrose (HS) (B, 10x), or high-sucrose 
supplemented with D-fagomine (HS+FG) (C, 10x) diet for 24 weeks and estimation of 
steatosis (D) and lipogranuloma (E).  
Values are in frequencies (percentage of animals that present the value, or do not). 
Comparisons were performed using χ2 statistics. ** P < 0.01 and *** P < 0.001 vs STD 
group; δδδ P < 0.001 vs HS group.
Figure 5. Hepatic levels of DAG 32:1 (A), DAG 32:2 (B), DAG 34:1 (C) and DAG 
36:2 (D) in WKY rats fed a standard (STD), high-sucrose (HS), or high-sucrose 
supplemented with D-fagomine (HS+FG) diet for 24 weeks.  
Values are means with their standard errors. Comparisons were performed using one-
way ANOVA and Tukey’s tests. * P < 0.05 vs STD group. 





